Lead Product(s): Labetalol Hydrochloride
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership January 21, 2021
The five medicines include: diazepam, labetalol, lorazepam, fentanyl citrate and 0.9% sodium chloride injection. Deal aims support to healthcare providers, helping to meet the immediate and long-term supply needs of drugs necessary to a range of patient care interventions.